SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Arthur Ashe — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientArthur Ashe
Date of birth1943-07-10
IdentifiersMRN HR-ML013-SYN-TD; SSN (made up) 000-13-6620
Document date1989-07-13
AuthorVivian Tolliver, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month HIV and coronary disease review with depression screening. [S]

History of Present Illness

Mr. Ashe returns six months after his first visit. He has missed no doses. He has had no headache, weakness, rash, fever, or chest pain, and has not needed nitroglycerin. He is back to full-time writing and coaching. He gave a urine sample with this morning's blood tests. He answered the PHQ-9 with a score of 2 and has no thoughts of self-harm. He says that knowing his viral load is undetectable has eased his mind. [S]

ElementDetail
AdherenceNo missed doses
WorkFull-time writing and coaching
MoodPHQ-9 2; item 9 scored 0
HeartNo angina; nitroglycerin not used

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; weight up 0.8 kg
CardiovascularNegativeNo chest pain or palpitations
NeurologicalNegativeNo headache, seizure, or weakness
PsychiatricNegativeMood good; PHQ-9 score 2; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesiumOne tablet by mouth once dailyOral route1988-09-25activeS
Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intakeThree tablets by mouth daily after a 200 mg loading doseOral route1988-09-11 to 1988-10-23completedS
Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intakeThree tablets by mouth every 6 hoursOral route1988-09-11 to 1988-10-23completedS
Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intakeTwo tablets by mouth dailyOral route1988-09-11 to 1988-10-23completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1988-10-23 to 1989-10-19completedS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1979-07-31activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1979-08-01activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1989-01-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route1979-08-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1989-07-13Body height185cmS
1989-07-13Body weight74.6kgS
1989-07-13Body mass index (BMI) [Ratio]21.8kg/m2S
1989-07-13Systolic blood pressure118mm[Hg]S
1989-07-13Diastolic blood pressure72mm[Hg]S
1989-07-13Heart rate66/minS
1989-07-13Respiratory rate14/minS
1989-07-13Body temperature36.6CelS
1989-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1989-07-13HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection0{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedNormalS
1989-07-13CD3+CD4+ (T4 helper) cells [#/volume] in Blood262/uL500-1500 /uLLowS
1989-07-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1989-07-13Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1989-07-13Creatinine [Mass/volume] in Serum or Plasma1.14mg/dL0.74-1.35 mg/dLNormalS
1989-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1989-07-13Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
1989-07-13Albumin/Creatinine [Mass Ratio] in Urine12mg/g<=29 mg/gNormalS
1989-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S

Physical Exam

Vital signs recorded on 1989-07-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 74.6 kg, blood pressure 118/72
CardiovascularRegular rhythm; no murmur; no edema
NeurologicalNo focal deficit

Problems

ProblemClinical statusVerificationCodeProvenance
HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infectionactiveconfirmed B20S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled.
Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapyactiveconfirmed B58.2S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass.
Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1942 and 1946 operationsactiveconfirmed I25.10S — Synthetic modern diagnosis; the history remains D.
Old myocardial infarction at age 36activeconfirmed I25.2S — Synthetic coded history of the documented 1979 heart attack.
Hyperlipidemia, on high-intensity statinactiveconfirmed E78.5S — Synthetic diagnosis; no cholesterol value from his lifetime is used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHIV-1 viral load4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 monthsCompleted todayNot detected (below 20 copies/mL), the second undetectable result
LaboratoryCD4 countEvery 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ARTCompleted today262 cells/uL
Medication safetyART adherence and drug-interaction review (antacids, calcium, iron, new medicines)Every visitCompleted todayNo missed doses; no interacting medicines
LaboratoryComplete blood countEvery 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ARTUp to dateNormal three months ago; next at nine months
LaboratoryPotassium, creatinine, and eGFR1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 monthsCompleted todayPotassium 4.6 mmol/L, creatinine 1.14 mg/dL, eGFR 80
LaboratoryUrine albumin-to-creatinine ratio on tenofovirAt the start of tenofovir and yearlyCompleted todayAlbumin-to-creatinine ratio 12 mg/g, normal; collected late after the deviations recorded at four weeks and three months; no harm resulted
LaboratoryALTEvery 6 months on ART; with symptoms on a statinUp to dateALT 27 U/L three months ago
Medication safetyToxoplasma maintenance therapy and stopping criteriaContinue until CD4 above 200 for more than 6 months on ART with a suppressed viral loadCompleted todayCD4 above 200 for three months; continue to nine months
Medication safetyPneumocystis prophylaxisWhile CD4 below 200; stop after more than 3 months above 200Completed todayCD4 above 200 for three months; covered by the maintenance dose, which continues
ExaminationNeurological check: headache, seizure, weakness, and right-hand strengthEvery visitCompleted todayNo symptoms
Self-managementRecombinant zoster vaccineTwo doses 2 to 6 months apart, from age 18 with HIVDueDose 2 at the preventive visit next month
Self-managementPsychosocial support, disclosure on his terms, and U=U counselingEvery visitCompleted todayReassured by his undetectable results; disclosure remains his decision
SurveyDepression screen (PHQ-9 or PHQ-2)At intake, at six months, and yearlyCompleted todayPHQ-9 2, with item 9 scored 0
ExaminationBlood pressure (goal below 130/80)Every visitCompleted today118/72 mmHg
ExaminationWeight, BMI, and physical activityEvery visitCompleted today74.6 kg, BMI 21.8; full-time work and exercise three times a week
Self-managementTobacco useEvery visitCompleted todayNever used tobacco
Medication safetyCoronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibeEvery visitCompleted todayTaking all three
Self-managementAngina review and chest-pain planEvery visitCompleted todayNo angina
LaboratoryLipid panel4 to 12 weeks after a change, then every 3 to 12 months; yearly when stableUp to dateLDL 52 mg/dL three months ago; yearly from now on
ImagingStress testing, coronary imaging, or echocardiographyOnly with new or worsening symptoms; routine surveillance not recommendedNot indicatedNo symptoms

Goal progress:

Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)

Follow-up: Preventive visit next month with the second zoster dose. Nine-month HIV review with blood tests. Next scheduled visit 1989-08-17: periodic adult preventive visit. [S]